Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
REVIEW
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer [Review]
Hiroshi E. Takami
Author information
Keywords: Molecularly targeted drugs, Kinase inhibitors, Differentiated thyroid carcinoma, Medullary thyroid carcinoma
JOURNAL FREE ACCESS

2011 Volume 58 Issue 3 Pages 151-153

View "Advance Publication" version (March 4, 2011).
Details
Download PDF (410K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted drugs. Some of these drugs, i.e., vandetanib, XL-184, sorafenib, motesanib, axitinib, and pazopanib, are clearly useful clinically.
Content from these authors
© The Japan Endocrine Society
Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Endocrinologia Japonica

Share this page
feedback
 Top